![Christopher J. Forlenza, MD](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/node/39545/3x2/forlenza_150429_1200x800.jpg?h=10d202d3)
Christopher J. Forlenza, MD
Pediatric Hematologist-Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Pediatric Hematology/Oncology
- Pediatric Leukemia and Lymphoma, Histiocytic Disorders
Request an Appointment
About Me
- Assistant Attending Physician
I am a member of the MSK Kids team who specializes in the care of children and young adults with blood (hematologic) cancers, including leukemias and lymphomas. I specialize in the treatment of Hodgkin lymphoma that has come back (relapsed) after prior therapy. I also care for patients with histiocytic disorders, including Langerhans cell histiocytosis.
Read more
In addition to caring for patients, I am conducting research to develop and assess better treatments. My research focuses on the development of novel therapies and treatment approaches for patients with lymphoma, with aim to improve their outcomes and minimize long-term side effects. I am MSK’s institutional Principal Investigator for the Children’s Oncology Group, the nation’s largest collaborative clinical research organization focused on childhood cancers.
When I meet a patient and family, I approach them with honesty, regardless of their age. I emphasize that this journey is something we are embarking on together. I thoroughly review their treatment options, emphasizing how the therapies we now have for their cancer have evolved.
I chose this field because as a physician, I can be on the cutting-edge of exciting technologies and emerging therapies. I am able to develop strong bonds with our patients and their families through difficult times, which often last for years. I support children and young adults as they battle through the worst times of their lives and am enormously gratified when I am able to watch them develop into healthy and successful adults.
A pediatric hematologist-oncologist is a doctor who treats cancers of the blood in children and adolescents. This doctor is a hematologist (HEE-muh-TAH-loh-jist) who diagnoses and treats blood disorders. They also are an oncologist (cancer doctor).
My Specialties
- Pediatric Hematology/Oncology
- Pediatric Leukemia and Lymphoma, Histiocytic Disorders
Education
- MD, New York University School of Medicine
Residencies
- Montefiore Medical Center/Albert Einstein College of Medicine
Fellowships
- Memorial Sloan Kettering Cancer Center
Board Certifications
- Pediatrics, Pediatric Hematology/Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
![Women talking](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/paragraph/131881/cta_image/app-220128-006_rt_1200x800.jpeg?h=10d202d3)
New Patients
Current Patients
Contact and Location
Dr. Forlenza sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Forlenza
- A Phase 2 Study of Cobimetinib in People With Langerhans Cell Histiocytosis and Other Histiocytic Disorders
- A Phase II International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
- A Phase III Study of Nivolumab in Combination with Chemo-Immunotherapy to Treat Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
- Clinical Trials Co-Investigated by Dr. Forlenza
- A Phase 2 Study of Nanatinostat and Valganciclovir in People With Lymphoma
Read more
- A Phase II Study of Dabrafenib plus Trametinib after Radiation Therapy for Newly Diagnosed High-Grade Glioma
- A Phase II Study of Inotuzumab Ozogamicin in Children and Young Adults with Recurrent or Persistent B-Cell Acute Lymphoblastic Leukemia
- A Phase II Study of Pembrolizumab Immunotherapy plus Involved Site Radiation Therapy to Treat Early Recurrent or Persistent Hodgkin Lymphoma
- A Phase III Study Comparing Standard Chemotherapy to Treatment with CPX-351 and/or Gilteritinib for Children Newly Diagnosed with Acute Myeloid Leukemia
- A Phase III Study of Accelerated versus Standard Chemotherapy for Patients with Intermediate- and Poor-Risk Metastatic Germ Cell Tumors
- A Phase III Study of Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed Standard-Risk or Down Syndrome B-Lymphoblastic Leukemia and Patients with Localized B-Lymphoblastic Lymphoma
- A Phase III Study of Imatinib plus Chemotherapy According to Disease Risk in Young Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- A Phase III Study of Selumetinib versus Carboplatin/Vincristine in Patients with Low-Grade Glioma
![Smiling doctors in the lab](/themes/mskcc/images/clinicaltrials_small.png)
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Forlenza’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Christopher J. Forlenza discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].